Advances in Multiple Stimuli-Responsive Drug-Delivery Systems for Cancer Therapy

Ruixin Jia,1,* Lesheng Teng,2,* Lingyu Gao,1 Ting Su,1 Lu Fu,3 Zhidong Qiu,1 Ye Bi1,4 1College of Pharmacy, Changchun University of Chinese Medicine, Changchun, Jilin, People’s Republic of China; 2School of Life Science, Jilin University, Changchun, Jilin, People’s Republic of Ch...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jia R, Teng L, Gao L, Su T, Fu L, Qiu Z, Bi Y
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	multi-stimuli responsive nanoparticles drug delivery tumor microenvironment oncotherapy Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/83db8a9518a04b04a449e209ca0f55b9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:83db8a9518a04b04a449e209ca0f55b9
record_format	dspace
spelling	oai:doaj.org-article:83db8a9518a04b04a449e209ca0f55b92021-12-02T13:43:49ZAdvances in Multiple Stimuli-Responsive Drug-Delivery Systems for Cancer Therapy1178-2013https://doaj.org/article/83db8a9518a04b04a449e209ca0f55b92021-02-01T00:00:00Zhttps://www.dovepress.com/advances-in-multiple-stimuli-responsive-drug-delivery-systems-for-canc-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Ruixin Jia,1,* Lesheng Teng,2,* Lingyu Gao,1 Ting Su,1 Lu Fu,3 Zhidong Qiu,1 Ye Bi1,4 1College of Pharmacy, Changchun University of Chinese Medicine, Changchun, Jilin, People’s Republic of China; 2School of Life Science, Jilin University, Changchun, Jilin, People’s Republic of China; 3College of Life Science, Jilin Agricultural University, Changchun, Jilin, People’s Republic of China; 4Practice Training Center, Changchun University of Chinese Medicine, Changchun, Jilin, People’s Republic of China*These authors contributed equally to this workCorrespondence: Ye BiPractice Training Center, Changchun University of Chinese Medicine, 1035 Boshuo Road, Changchun, Jilin, People’s Republic of ChinaTel/Fax +86-431-86763979Email biye88@outlook.comZhidong QiuCollege of Pharmacy, Changchun University of Chinese Medicine, 1035 Boshuo Road, Changchun, Jilin, People’s Republic of ChinaTel/Fax +86-431-86763979Email qzdcczy@163.comAbstract: Nanomedicines afford unique advantages in therapeutic intervention against tumors. However, conventional nanomedicines have failed to achieve the desired effect against cancers because of the presence of complicated physiological fluids and the tumor microenvironment. Stimuli-responsive drug-delivery systems have emerged as potential tools for advanced treatment of cancers. Versatile nano-carriers co-triggered by multiple stimuli in different levels of organisms (eg, extracorporeal, tumor tissue, cell, subcellular organelles) have aroused widespread interest because they can overcome sequential physiological and pathological barriers to deliver diverse therapeutic “payloads” to the desired targets. Furthermore, multiple stimuli-responsive drug-delivery systems (MSR-DDSs) offer a good platform for co-delivery of agents and reversing multidrug resistance. This review affords a comprehensive overview on the “landscape” of MSR-DDSs against tumors, highlights the design strategies of MSR-DDSs in recent years, discusses the putative advantage of oncotherapy or the obstacles that so far have hindered the clinical translation of MSR-DDSs.Keywords: multi-stimuli responsive nanoparticles, drug delivery, tumor microenvironment, oncotherapyJia RTeng LGao LSu TFu LQiu ZBi YDove Medical Pressarticlemulti-stimuli responsive nanoparticlesdrug deliverytumor microenvironmentoncotherapyMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 16, Pp 1525-1551 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	multi-stimuli responsive nanoparticles drug delivery tumor microenvironment oncotherapy Medicine (General) R5-920
spellingShingle	multi-stimuli responsive nanoparticles drug delivery tumor microenvironment oncotherapy Medicine (General) R5-920 Jia R Teng L Gao L Su T Fu L Qiu Z Bi Y Advances in Multiple Stimuli-Responsive Drug-Delivery Systems for Cancer Therapy
description	Ruixin Jia,1,* Lesheng Teng,2,* Lingyu Gao,1 Ting Su,1 Lu Fu,3 Zhidong Qiu,1 Ye Bi1,4 1College of Pharmacy, Changchun University of Chinese Medicine, Changchun, Jilin, People’s Republic of China; 2School of Life Science, Jilin University, Changchun, Jilin, People’s Republic of China; 3College of Life Science, Jilin Agricultural University, Changchun, Jilin, People’s Republic of China; 4Practice Training Center, Changchun University of Chinese Medicine, Changchun, Jilin, People’s Republic of China*These authors contributed equally to this workCorrespondence: Ye BiPractice Training Center, Changchun University of Chinese Medicine, 1035 Boshuo Road, Changchun, Jilin, People’s Republic of ChinaTel/Fax +86-431-86763979Email biye88@outlook.comZhidong QiuCollege of Pharmacy, Changchun University of Chinese Medicine, 1035 Boshuo Road, Changchun, Jilin, People’s Republic of ChinaTel/Fax +86-431-86763979Email qzdcczy@163.comAbstract: Nanomedicines afford unique advantages in therapeutic intervention against tumors. However, conventional nanomedicines have failed to achieve the desired effect against cancers because of the presence of complicated physiological fluids and the tumor microenvironment. Stimuli-responsive drug-delivery systems have emerged as potential tools for advanced treatment of cancers. Versatile nano-carriers co-triggered by multiple stimuli in different levels of organisms (eg, extracorporeal, tumor tissue, cell, subcellular organelles) have aroused widespread interest because they can overcome sequential physiological and pathological barriers to deliver diverse therapeutic “payloads” to the desired targets. Furthermore, multiple stimuli-responsive drug-delivery systems (MSR-DDSs) offer a good platform for co-delivery of agents and reversing multidrug resistance. This review affords a comprehensive overview on the “landscape” of MSR-DDSs against tumors, highlights the design strategies of MSR-DDSs in recent years, discusses the putative advantage of oncotherapy or the obstacles that so far have hindered the clinical translation of MSR-DDSs.Keywords: multi-stimuli responsive nanoparticles, drug delivery, tumor microenvironment, oncotherapy
format	article
author	Jia R Teng L Gao L Su T Fu L Qiu Z Bi Y
author_facet	Jia R Teng L Gao L Su T Fu L Qiu Z Bi Y
author_sort	Jia R
title	Advances in Multiple Stimuli-Responsive Drug-Delivery Systems for Cancer Therapy
title_short	Advances in Multiple Stimuli-Responsive Drug-Delivery Systems for Cancer Therapy
title_full	Advances in Multiple Stimuli-Responsive Drug-Delivery Systems for Cancer Therapy
title_fullStr	Advances in Multiple Stimuli-Responsive Drug-Delivery Systems for Cancer Therapy
title_full_unstemmed	Advances in Multiple Stimuli-Responsive Drug-Delivery Systems for Cancer Therapy
title_sort	advances in multiple stimuli-responsive drug-delivery systems for cancer therapy
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/83db8a9518a04b04a449e209ca0f55b9
work_keys_str_mv	AT jiar advancesinmultiplestimuliresponsivedrugdeliverysystemsforcancertherapy AT tengl advancesinmultiplestimuliresponsivedrugdeliverysystemsforcancertherapy AT gaol advancesinmultiplestimuliresponsivedrugdeliverysystemsforcancertherapy AT sut advancesinmultiplestimuliresponsivedrugdeliverysystemsforcancertherapy AT ful advancesinmultiplestimuliresponsivedrugdeliverysystemsforcancertherapy AT qiuz advancesinmultiplestimuliresponsivedrugdeliverysystemsforcancertherapy AT biy advancesinmultiplestimuliresponsivedrugdeliverysystemsforcancertherapy
_version_	1718392564677083136

Advances in Multiple Stimuli-Responsive Drug-Delivery Systems for Cancer Therapy

Ejemplares similares